Mablink’s R&D team authored a scientific article published today (March 9) in the journal “Pharmaceuticals”.
The paper “Exatecan Antibody Drug Conjugates based on a hydrophilic polysarcosine Drug-Linker platform” characterizes a proof-of-concept trastuzumab (anti-HER2) DAR8 PSAR Exatecan ADC based on Mablink’s proprietary PSARlink hydrophilic platform and compares it to 2 marketed ADC: Kadcyla (Roche) and Enhertu (Daiichi Sankyo). The preclinical in vitro and in vivo experiments demonstrate a superiority of Mablink’s ADC in models of breast and gastric cancers.
You can access it here: article link.